Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Capital Expenditures (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Capital Expenditures over the past 12 years, most recently at $240000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $240000.0 for Q4 2025, up 110.53% from a year ago — trailing twelve months through Dec 2025 was $495000.0 (down 3.13% YoY), and the annual figure for FY2025 was $495000.0, down 3.13%.
  • Capital Expenditures for Q4 2025 was $240000.0 at Viridian Therapeutics, Inc.\DE, up from $127000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for VRDN hit a ceiling of $873000.0 in Q4 2023 and a floor of -$289000.0 in Q3 2023.
  • Median Capital Expenditures over the past 5 years was $123500.0 (2021), compared with a mean of $168833.3.
  • Peak annual rise in Capital Expenditures hit 277.92% in 2023, while the deepest fall reached 404.21% in 2023.
  • Viridian Therapeutics, Inc.\DE's Capital Expenditures stood at $84000.0 in 2021, then surged by 175.0% to $231000.0 in 2022, then surged by 277.92% to $873000.0 in 2023, then crashed by 86.94% to $114000.0 in 2024, then surged by 110.53% to $240000.0 in 2025.
  • The last three reported values for Capital Expenditures were $240000.0 (Q4 2025), $127000.0 (Q3 2025), and $42000.0 (Q2 2025) per Business Quant data.